• About
    • Company Overview
    • Management Team
    • Board of Directors
    • Science Advisors
    • Neurology Advisors
    • Ophthalmology Advisors
    • Contacts
  • Science
    • Publications
    • Collaborators
  • Pipeline
    • Infantile Neuroaxonal Dystrophy (INAD)
    • Friedreich’s Ataxia (FA)
    • Amyotrophic Lateral Sclerosis (ALS)
    • Progressive Supranuclear Palsy (PSP)
    • Dry AMD
    • Future Targets
  • Patient Resources
    • Expanded Access Policy
    • Clinical Trials
    • Additional Resources
  • News & Events
    • Press Releases
    • News
    • Events
    • Videos
  • Careers
HomeSciencePublicationsThe natural history of infantile neuroaxonal dystrophy

The natural history of infantile neuroaxonal dystrophy

Background

Infantile neuroaxonal dystrophy (INAD) is a rapidly progressive neurodegenerative disorder of early onset causing premature death. It results from biallelic pathogenic variants in PLA2G6, which encodes a calcium-independent phospholipase A2.

Objective

We aim to outline the natural history of INAD and provide a comprehensive description of its clinical, radiological, laboratory, and molecular findings.

Materials and methods

We comprehensively analyzed the charts of 28 patients: 16 patients from Riyadh, Saudi Arabia, 8 patients from North and South America and 4 patients from Europe with a molecularly confirmed diagnosis of PLA2G6-associated neurodegeneration (PLAN) and a clinical history consistent with INAD.

Results

In our cohort, speech impairment and loss of gross motor milestones were the earliest signs of the disease. As the disease progressed, loss of fine motor milestones and bulbar dysfunction were observed. Temporo-frontal function was among the last of the milestones to be lost. Appendicular spastic hypertonia, axial hypotonia, and hyperreflexia were common neurological findings. Other common clinical findings include nystagmus (60.7%), seizures (42.9%), gastrointestinal disease (42.9%), skeletal deformities (35.7%), and strabismus (28.6%). Cerebellar atrophy and elevations in serum AST and LDH levels were consistent features of INAD. There was a statistically significant difference when comparing patients with non-sense/truncating variants compared with missense/in-frame deletions in the time of initial concern (p = 0.04), initial loss of language (p = 0.001), initial loss of fine motor skills (p = 0.009), and initial loss of bulbar skills (p = 0.007).

Conclusion

INAD is an ultra-rare neurodegenerative disorder that presents in early childhood, with a relentlessly progressive clinical course. Knowledge of the natural history of INAD may serve as a resource for healthcare providers to develop a targeted care plan and may facilitate the design of clinical trials to treat this disease.

To read click here.

About
Science
  • Publications
Pipeline
  • Clinical
  • Preclinical
  • Future Targets
Patient Resources
  • Expanded Access Policy
News & Events
Careers
RETROTOPE, 4300 EL CAMINO REAL, SUITE 201, LOS ALTOS, CA 94022
Copyright ©️ 2015-2021 Retrotope Inc.
You are leaving Retrotope’s website. Retrotope does not guarantee the accuracy or completeness of the information contained on any third-party sites, nor does it endorse any of the opinions or information contained on those sites. Please click CONFIRM to continue. CONFIRM